Related Experiment Video
Updated: May 3, 2026

14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
34.4K
Biologic targeted therapy in allergic asthma
Jeffrey B Bice1, Evelyn Leechawengwongs2, Anthony Montanaro2
1School of Medicine, Tulane University, New Orleans, Louisiana.
Summary
Biologic therapies for asthma show promise, with many drugs in development. However, asthma
Area of Science:
- Pulmonology and immunology
- Pharmacology and drug development
Background:
- Asthma affects over 300 million people globally, with 5-10% experiencing severe, uncontrolled disease.
- The development of targeted biologic therapies for asthma has accelerated since 2003.
Purpose of the Study:
- To review current biologic targeted therapies for asthma, focusing on structure, function, clinical utility, and safety.
- To assess the landscape of novel biologic agents under investigation.
Main Methods:
- Comprehensive literature search of PubMed and OVID databases (June-November 2013).
- Selection of studies based on impact, relevance, and clinical significance.
- Emphasis on therapies targeting IgE, IL-4, IL-5, IL-13, TNF-α, CRTh2, and TLRs 7/9.
Main Results:
- Numerous biologic asthma therapies are in clinical trials and development, indicating a promising future.
- Despite setbacks, research continues to unravel asthma's complex pathophysiology.
- The goal is to personalize biologic therapies based on individual asthma phenotypes.
Conclusions:
- Biologic therapies for asthma have generated anticipation but often yielded disappointing results.
- Asthma is a complex syndrome with diverse genotypes and phenotypes, suggesting no single "magic bullet" cure.
- Further research is needed to develop effective, tailored biologic treatments for severe asthma.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
Antiasthma Drugs: β2-Adrenoceptor Agonists
2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Asthma I: Introduction
112
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
112

